Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Esophageal Squamous Cell Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Esophageal Cancer (195
)
Esophageal Adenocarcinoma (39
)
Esophageal Cancer (195
)
Esophageal Adenocarcinoma (39
)
›
Associations
(90)
News
Trials
Search handles
@ArndtVogel
@DrChoueiri
@FilippoPietran4
@HosseinTaghiz11
@KlempnerSam
@LAbushahin
@MLPOncoData
@TimothyJBrownMD
@ilyassahinMD
@jgong15
@ryanhuey
@singhv2003
Search handles
@ArndtVogel
@DrChoueiri
@FilippoPietran4
@HosseinTaghiz11
@KlempnerSam
@LAbushahin
@MLPOncoData
@TimothyJBrownMD
@ilyassahinMD
@jgong15
@ryanhuey
@singhv2003
Filter by
Latest
10ms
Great discussion by @KoheiShitara and team of therapeutic biomarker results from LUD2015-005 (mostly EAC) and JUPITER-06 (ESCC), and potential future directions: https://t.co/QxYT1c5UXq (@_tom_dot_com)
10 months ago
10ms
Research exploring #predictive effects of two common genes associated with Tertiary Lymphoid Structures models on #prognosis and #immunotherapy effects in Esophageal squamous cell carcinoma patients 🔗https://t.co/fe5for4JiZ @DraMartinezLago @KEN_K_ @ISDE_net #GITwitter (@TumoriJ)
10 months ago
Clinical
10ms
Checkpoint inhibition in ESCC by Markus Möhler at #WCGIC2023 @myESMO @WCGIC (@HosseinTaghiz11)
10 months ago
Checkpoint inhibition
10ms
Great question. used to offer to ESCC and then CM577 made things muddy. Data shows PET, EUS are unreliable for detecting residual disease in adenocarcinoma even with the bite on bite technique in preSANO. MRI? Data suggest it’s better but need more. (@LAbushahin)
10 months ago
10ms
Sir, is there any role of Anti-EGFR monoclonal antibodies based on ASCO 2022 - NXCEL1311 Study in LA-ESCC? (@amit_dr020)
10 months ago
11ms
低リスクの早期 #子宮頸がん(ESCC)で #単純子宮全摘出術 を受けた患者の3年骨盤内再発率は #広汎子宮全摘出術 を受けた患者と同等で、手術合併症はより少なくQOLはより良好であることが明らかになりました。 #ASCO2023 https://t.co/ottSGBsT13 (@cancer_navi)
11 months ago
12ms
Sharing our reply re efficacy of ICI in ESCC with regard to JUPITER-06. @sundar__raghav @FilippoPietran4 https://t.co/B7VebIZZ1g Working & code: https://t.co/R62kFToz9z (@josephjzhao)
12 months ago
Clinical
12ms
Delayed post—@MimiTanMD gave a fantastic talk this morning @DDWMeeting on optimizing an AI algorithm for the HRME microendoscope for ESCC detection. More to come from Dr. Tan and fellow colleagues at @bcm_gihep and @Rice_BIOE on AI with HRME! @anandasabapathy. #DDW2023 (@NMansourMD)
12 months ago
1year
💭 #JCO #Correspondence: Validity of meta-analytical estimates and hazard ratios quantifying survival benefit of Immunochemotherapy in low programmed death ligand 1-expressing #EsophagealSquamousCellCarcinoma 👉 https://t.co/QJ9BZI7gBr #esocsm #ImmunoOnc (@JCO_ASCO)
1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
1year
Esophageal squamous cell ca:pts with a PD-L1 CPS of less than10,medianOS was10.5months in pembrolizum ab200 mg+5-FU at800mg/m2 on days 1–5&cisplatin 80mg/m2 on day 1 for up to 6 cycles. Tt was repeated once every 3wks for up to 35 cycles versus 10.6 months in placebo+chemotherapy (@singhv2003)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
cisplatin • 5-fluorouracil
1year
Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A #Metaanalysis Including Low PD-L1 Subgroups https://t.co/i5LbJSoO75 (@MLPOncoData)
1 year ago
Retrospective data • Checkpoint inhibition • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1-L
1year
🔥First-line serplulimab or placebo + CTx in PD-L1+ esophageal squamous cell carcinoma @NatureMedicine https://t.co/qH0Y2x1C6s ✅🇨🇳Phs-III 551 pts 👉mOS: 15.3 vs 11.8 mo 👉mPFS: 5.8 vs 5.3 mo 👉ORR: 57.6 vs 42.1% 🧐Best cut off for CPS/TPS needs to be defined @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Hansizhuang (serplulimab)
1year
Out in @NatureMedicine and adding to phase III frontline ESCC data. ASTRUM-007 trial of 1L chemo + serplulimab/placebo in PD-L1+ (CPS >=1) ESCC. Full text -- https://t.co/02Qv3Mv1Nz Dual Primary = PFS/OS. PFS HR = 0.6 (ab diff 5.8 vs 5.3m, OS HR 0.68 (abs diff 15.3 vs 11.8) (@KlempnerSam)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Hansizhuang (serplulimab)
over1year
@KEN_K_ 29-mo fu CM648 #1L adv #ESCC PD-L1+ shows OS benefit w/chemo + nivo and nivo/ipi over platinum-based chemo, subgroup analysis show “dose-dependent” PD-L1 positivity impact on benefit to both chemo-nivo and nivo/ipi in adv ESCC @asco #GI23 (@jgong15)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over1year
29 month follow-up of CM648 in advanced ESCC (nivo+chemo vs chemo, nivo+ipi vs chemo). OS, PFS benefit maintained, driven by the PDL1 >1% population with nivo-chemo vs chemo. Ipi/Nivo also maintains OS benefit but no PFS benefit vs chemo #GI23 (@TimothyJBrownMD)
over 1 year ago
Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over1year
🔥NIVO + CTx or IPI vs CTX as 1L for ESCC @ ASCO-GI 2023 ✅ 29-mo follow-up CheckMate 648 👉mOS PDL1 >1%: 15 vs 13.1 vs 9.1 👉mPFS PDL1 >1%: 6.8 vs 4.0 vs 4.4 👉DOR >24 mo: 22%, 36%, 13 👉Continuous value of both IO therapies @myESMO @OncoAlert (@ArndtVogel)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab)
over1year
Efficacy of ICI in ESCC patients with low PDL1 expression: Our pooled analysis shows there may not be OS benefit in TPS<1% pts. Harmonised biomarkers needed for better pt selection @FilippoPietran4 @sundar__raghav @NickyWongZH @josephjzhao https://t.co/lvsUXceGu8 @JAMAOnc (@dominicyap_)
over 1 year ago
Retrospective data • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-1-L • PD-L1-L
over1year
KMs in unreported PDL1 low subgroups of pts with ESCC on ICI ➡️TPS is an important selection biomarker in line with EMA approval ➡️PD-L1 is less important in Asian pts! ➡️future: harmonize PDL1 test TY Singapore group @sundar__raghav @dominicyap_ https://t.co/fntQZtHE9S @JAMAOnc (@FilippoPietran4)
over 1 year ago
Clinical • European regulatory • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-1-L • PD-L1-L
over1year
This study provides novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced #ESCC with low PD-L1 expression. #immunotherapy #cancer https://t.co/ksLR2Wa7J1 (@ilyassahinMD)
over 1 year ago
Clinical • Head-to-Head • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1-L
over1year
🔥Just published @LancetLongevity: RAMONA trial in elderly pts with oesophageal squamous cell cancer🔥 https://t.co/3l1NCZOwZx ✅66pts, Nivo -> Nivo/IPI escalation 👉44 Nivo/IPI, 22 Nivo alone 👉mOS: 7.2 mo, PDL1>5% predictive 🔥 OS⬆️than historical controls @myESMO @OncoAlert (@ArndtVogel)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
almost2years
JUST IN: @US_FDA approved Nivo+Ipi for 1L metastatic esophageal squamous cell carcinoma: OS was significant in all randomized pts in CHECKMATE-648 trial (HR 0.74 (p=0.002) nivo/chemo-arm & 0.78 (p=0.01) N/I vs chemo). Also OS + in PD-L1+ pts. @OncoAlert (@DrChoueiri)
almost 2 years ago
Clinical • FDA event
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over2years
Dr. Ian Chau summarizes immunotherapy approvals in squamous cell carcinoma of the esophagus at #GI22. AND points out the $1M question of PD-L1 CPS... (@ryanhuey)
over 2 years ago
PD-L1 (Programmed death ligand 1)
over2years
#TumorBoardTuesday #PrecisionMedicine #GITwitter KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review https://t.co/qN633I6cTY (@ShimaghavimiMD)
over 2 years ago
Review
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • BRAF mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login